LivaNova

Cadence Neuroscience, Inc. is an early-stage company founded in 2017 and headquartered in Redmond, Washington. It specializes in developing innovative medical device therapies aimed at treating epilepsy, central pain, and other neurological disorders. The company’s core technology, developed at the Mayo Clinic, is currently under clinical evaluation. Cadence Neuroscience's medical devices are designed to detect specific brain signals and deliver targeted electrical stimulation, allowing for tailored brain stimulation therapies. This approach enhances seizure control and aims to improve treatment outcomes for patients with neurological issues compared to existing protocols.

ALung Technologies, Inc., established in 1997 and based in Pittsburgh, Pennsylvania, specializes in developing and manufacturing medical devices for treating acute respiratory failure. The company's primary product is the Hemolung Respiratory Assist System, a dialysis-like device that removes carbon dioxide and delivers oxygen directly to the blood, allowing patients' lungs to rest and heal while avoiding intubation and facilitating protective ventilation.

Noctrix Health, Inc. is an early-stage medical device company founded in 2018 and based in Menlo Park, California. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on conditions such as restless leg syndrome. Noctrix Health's innovative devices leverage neural circuitry to alleviate symptoms, promoting undisturbed sleep and allowing patients to manage their chronic medical conditions more effectively.

ShiraTronics, Inc. is a company focused on developing and commercializing innovative therapies for the treatment of chronic migraines. Incorporated in 2018 and headquartered in Ireland, with an additional location in Minneapolis, Minnesota, ShiraTronics utilizes advanced neuromodulation technology to address the unmet clinical needs of patients suffering from debilitating migraine headaches. The company's mission is to transform the lives of those affected by this widespread and disabling disorder, which impacts millions globally, by providing effective solutions that enhance their quality of life.

Ceribell, Inc. is a medical technology company based in Mountain View, California, that specializes in the design and manufacture of devices for acquiring and interpreting electroencephalography (EEG) data. Founded in 2014, Ceribell focuses on making EEG technology more accessible, efficient, and cost-effective, particularly in acute care settings. The company's flagship product, the Ceribell EEG System, includes a portable EEG headband and a compact recorder that provide clinical-quality EEG results without the need for a trained EEG technologist. This system can be set up by healthcare providers in just six minutes, facilitating quicker clinical decision-making. An innovative feature of the Ceribell System is its Brain Stethoscope function, which translates brainwave patterns into sound to aid in the detection of seizures, including non-convulsive seizures. This capability enables earlier diagnosis and targeted treatment, potentially reducing mortality, length of hospital stays, and the risk of complications for patients with serious neurological conditions.

TandemLife is a medical device company that specializes in developing, manufacturing, and marketing innovative products for circulatory support. Their flagship product, the TandemHeart System, is an FDA-cleared device designed to provide extracorporeal circulatory support quickly, making it suitable for use by cardiologists in catheterization labs and cardiac surgeons in operating rooms. The system can deliver up to 5.0 liters per minute of circulatory support percutaneously and up to 8.0 liters per minute with direct surgical cannulation. It consists of a pump that circulates oxygenated blood, a set of cannulae for connecting the pump to the patient, and controllers that manage power, lubrication, and system monitoring. TandemLife's devices are aimed at improving outcomes for patients requiring temporary heart support and reducing healthcare costs.

ImThera Medical, Inc. is a medical device company based in San Diego, California, focused on developing innovative solutions for the treatment of obstructive sleep apnea (OSA). Founded in 2004, the company specializes in implantable neurostimulation devices, notably the aura6000, which is part of its THN Sleep Therapy system. This system employs hypoglossal neurostimulation technology to deliver mild stimulation to key tongue muscles during sleep, thereby maintaining upper airway patency and significantly reducing OSA events. With an estimated 28 million Americans affected by OSA, ImThera aims to provide a viable alternative to traditional therapies, such as CPAP, which often face compliance challenges. By addressing the underlying mechanisms of OSA, ImThera Medical seeks to enhance patient quality of life and alleviate the associated healthcare costs.

HighLife is a medical technology company specializing in Transcatheter Mitral Valve Replacement (TMVR) aimed at treating mitral valve regurgitation. Founded in 2010 by Georg Börtlein, the company is developing a minimally invasive prosthetic mitral valve designed to be implanted on a beating heart, allowing for the preservation of the native valve structure and surrounding anatomy. HighLife's innovative system facilitates a transseptal delivery through the femoral vein, enabling a reversible approach that minimizes trauma to patients during surgical procedures. The technology is currently undergoing clinical evaluation, with a focus on ensuring ease and safety of use for healthcare providers.

Caisson Interventional, LLC, established in 2012 and headquartered in Maple Grove, Minnesota, operates as a subsidiary of LivaNova PLC since May 2017. The company is a clinical-stage medical device manufacturer specializing in the design, development, and evaluation of a novel percutaneous mitral valve replacement system. This innovative system is intended for delivery across the heart's septum via the femoral vein, offering the flexibility to be repositioned or withdrawn before final deployment.

MD Start SA is a medical technology incubator based in Lausanne, Switzerland, that specializes in transforming innovative ideas into viable medical solutions. Founded in 2009, the company creates, develops, and operates medical projects, effectively turning them into new companies. MD Start employs both strategic and hands-on approaches to guide these projects through the investment stage and into commercial development. The firm collaborates with notable partners in the medical device sector, including Medtronic, Sofinnova Partners, and Versant Ventures, among others. Through its focused efforts, MD Start aims to support the growth of medical device start-ups and facilitate the advancement of healthcare technologies.

Cyberonics is a company dedicated to developing and marketing medical device solutions for individuals suffering from epilepsy, depression, and other chronic disorders. Their focus is on improving the lives of patients and their families through innovative and patient-focused technology. With a commitment to advancing device-based solutions, Cyberonics aims to provide effective and accessible treatment options for those in need.